Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2022-05-20 Lipidor Lipidor uppdaterar om Fas III-studien med AKP02 för behandling av psoriasis - hälften av patienterna rekryterade Pressreleaser Ladda ner | Visa Stäng
2022-05-20 Lipidor Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 20 May 2022 | Lipidor

Lipidor updates on Phase III study of AKP02 in treatment of psoriasis – half of patients now recruited

On 26 January, Lipidor announced that the first psoriasis patients had been enrolled in the company’s Phase III clinical trial of AKP02 cutaneous spray. The observer-blind and placebo-controlled Phase III study included a total of 294 patients. The aim of the study is to show a good therapeutic effect for treatment of mild to moderate psoriasis on both body and scalp. The Phase III study also measures quality of life, and patient satisfaction, to demonstrate the associated benefits of AKP02 that may be significant for future commercialization. The trial is fully funded with existing cash and is conducted by Cadila Pharmaceuticals, which successfully completed the Phase III study with its predecessor AKP01.

With the current patient recruitment rate, the last patient is expected to commence treatment in June and topline results from the Phase III study with AKP02 are expected in the third quarter of 2022. Lipidor and the company’s commercial partner RELIFE, a company in the Menarini group, are already working together to ensure that the two topical drug candidates, AKP01 and AKP02, become available for treatment for mild to moderate psoriasis in Europe, the CIS countries and Turkey. Conditions for new commercial agreements are continuously investigated and there is great interest from the market.

The psoriasis candidate AKP02 combines calcipotriol and betamethasone dipropionate and is based on Lipidor’s patented AKVANO® technology. Lipidor has elected to compare the sprayable drug candidate AKP02 with Enstilar, which is a commonly prescribed foam preparation for topical treatment of psoriasis. AKP02 contains the same combination of active substances as Enstilar.

Positive results from the Phase III study with Lipidor’s drug candidate AKP01, which is based on calcipotriol alone, show that AKVANO® technology works well for drugs for treatment of psoriasis. The preclinical studies with AKP02 also show promising results. The goal of AKP02 is to offer a patient-friendly, spray-based treatment for mild to moderate psoriasis.

”It’s gratifying to see that participating clinics in the Phase III study are recruiting patients at a good pace,” says Ola Holmlund, Lipidor CEO. ”We look forward to presenting results from the study during the third quarter of 2022.”

Publication

The information was provided for publication by Lipidor’s CEO on 20 May 2022 at 8.30am CEST.

For more information, please contact:

Ola Holmlund, CEO
Telephone: +46 (0)72 50 70 369
Email: ola.holmlund@lipidor.se

Certified Adviser

Erik Penser Bank AB
Telephone: +46 (0)8 463 80 00
E-mail: certifiedadviser@penser.se (certifiedadviser@penser.se?subject=Lipidor%20AB)

About Lipidor AB

Lipidor AB (www.lipidor.se) is a Swedish,Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation ofprovenpharmaceutical substances.

2022-05-05 Lipidor Lipidor AB (publ) offentliggör delårsrapport för första kvartalet 2022 Rapporter Ladda ner | Visa Stäng
2022-05-05 Lipidor Lipidor AB (publ) publishes interim report for first quarter 2022 Rapporter Ladda ner | Visa Stäng
2022-05-03 Lipidor Lipidor: NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-05-03 Lipidor Lipidor: KALLELSE TILL ÅRSSTÄMMA I LIPIDOR AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-04-28 Lipidor Lipidor AB (publ) publishes annual report for 2021 Rapporter Ladda ner | Visa Stäng
2022-04-28 Lipidor Lipidor AB (publ) offentliggör årsredovisning för 2021 Rapporter Ladda ner | Visa Stäng
2022-03-25 Lipidor Lipidor strengthens its operational team and recruits Supply Chain & Operations Manager Pressreleaser Ladda ner | Visa Stäng
2022-03-25 Lipidor Lipidor stärker sitt operativa team och rekryterar Supply Chain & Operations Manager Pressreleaser Ladda ner | Visa Stäng
2022-03-15 Lipidor Lipidor: Animal health company Emollivet raises capital and strengthens team Pressreleaser Ladda ner | Visa Stäng
2022-03-15 Lipidor Lipidor: Djurhälsobolaget Emollivet tar in kapital och förstärker teamet Pressreleaser Ladda ner | Visa Stäng
2022-03-03 Lipidor Lipidor: Emollivet lanserar spray för hästar med mugg, rasp och skorv Pressreleaser Ladda ner | Visa Stäng
2022-03-03 Lipidor Lipidor: Emollivet launches spray for equestrian pastern dermatitis Pressreleaser Ladda ner | Visa Stäng
2022-02-23 Lipidor Lipidor AB (publ) publishes year-end report for 2021 Rapporter Ladda ner | Visa Stäng
2022-02-23 Lipidor Lipidor AB (publ) offentliggör bokslutskommuniké för 2021 Rapporter Ladda ner | Visa Stäng
2022-01-26 Lipidor Lipidor meddelar att de första patienterna har rekryterats till Fas III-studien med AKP02 för behandling av plackpsoriasis Pressreleaser Ladda ner | Visa Stäng
2022-01-26 Lipidor Lipidor Announces Enrolment of First Patients in a Phase III Study on AKP02 for Treatment of Psoriasis Pressreleaser Ladda ner | Visa Stäng
2021-12-17 Lipidor Lipidor expands clinical program, announces investment in new drug development project against acne vulgaris Pressreleaser Ladda ner | Visa Stäng
2021-12-17 Lipidor Lipidor utökar det kliniska programmet - offentliggör satsning på ett nytt läkemedelsutvecklingsprojekt mot akne Pressreleaser Ladda ner | Visa Stäng
2021-12-09 Lipidor Lipidor presenterar valberedningen Pressreleaser Ladda ner | Visa Stäng
2021-12-09 Lipidor Lipidor presents Nomination Committee Pressreleaser Ladda ner | Visa Stäng
2021-11-25 Lipidor Lipidor publishes interim report for period 1 January - 30 September and Q3 2021 Rapporter Ladda ner | Visa Stäng
2021-11-25 Lipidor Lipidor publicerar delårsrapport för perioden 1 januari - 30 september och det tredje kvartalet 2021 Rapporter Ladda ner | Visa Stäng
2021-10-29 Lipidor Lipidor submits new patent application and expands collaboration with Cannassure using Lipidor's AKVANO[®] technology for medicinal cannabis products Pressreleaser Ladda ner | Visa Stäng
2021-10-29 Lipidor Lipidor lämnar in en ny patentansökan och utökar samarbetet med Cannassure om medicinska cannabisprodukter baserade på Lipidors AKVANO[®]-teknologi Pressreleaser Ladda ner | Visa Stäng
2021-10-19 Lipidor Optionsinnehavare i Lipidor utnyttjar samtliga teckningsoptioner i incitamentsprogrammet 2018/2021 Pressreleaser Ladda ner | Visa Stäng
2021-10-19 Lipidor Warrant holders exercise all warrants in Lipidor's incentive program 2018/2021 Pressreleaser Ladda ner | Visa Stäng
2021-09-30 Lipidor BioStock: Lipidors fas III-studie är godkänd och startredo Pressreleaser Visa Stäng
2021-09-27 Lipidor Lipidor announces approval to start Phase III clinical study of drug candidate AKP02 for treatment of psoriasis Pressreleaser Ladda ner | Visa Stäng
2021-09-27 Lipidor Lipidor meddelar godkännande för studiestart av klinisk Fas III-studie av psoriasiskandidaten AKP02 Pressreleaser Ladda ner | Visa Stäng
2021-08-24 Lipidor Lipidor publicerar delårsrapport för H1 2021 Rapporter Ladda ner | Visa Stäng
2021-08-24 Lipidor Lipidor publishes interim report for H1 2021 Rapporter Ladda ner | Visa Stäng
2021-07-06 Lipidor Sommarbrev från Lipidor Pressreleaser Ladda ner | Visa Stäng
2021-07-06 Lipidor Summer letter from Lipidor Pressreleaser Ladda ner | Visa Stäng
2021-07-01 Lipidor Lipidor licensavtal ger Menarini Group-bolaget RELIFE Srl exklusiva rättigheter att registrera, marknadsföra, distribuera och sälja två nya psoriasis läkemedelskandidater med potentiellt värde 70 MEUR Pressreleaser Ladda ner | Visa Stäng
2021-07-01 Lipidor Lipidor AB licence agreement grants Menarini Group company, RELIFE Srl, exclusive rights to register, promote, distribute and market two new psoriasis drug candidates for potential value of MEUR 70 Pressreleaser Ladda ner | Visa Stäng
2021-06-08 Lipidor Bulletin from the Extraordinary General Meeting of Lipidor AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-06-08 Lipidor Kommuniké från extra bolagsstämma i Lipidor AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-06-08 Lipidor Kommuniké från årsstämma i Lipidor AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-06-08 Lipidor Bulletin from the annual general meeting of Lipidor AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-05-24 Lipidor KALLELSE TILL EXTRA BOLAGSSTÄMMA i Lipidor AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-05-24 Lipidor Lipidor: NOTICE OF EXTRAORDINARY GENERAL MEETING IN LIPIDOR AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-05-07 Lipidor KALLELSE TILL ÅRSSTÄMMA i Lipidor AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-05-07 Lipidor Lipidor: NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-05-06 Lipidor Lipidor publishes interim report for Q1 2021 Rapporter Ladda ner | Visa Stäng
2021-05-06 Lipidor Lipidor publicerar delårsrapport för Q1 2021 Rapporter Ladda ner | Visa Stäng
2021-04-23 Lipidor Lipidor publishes annual report for 2020 Rapporter Ladda ner | Visa Stäng
2021-04-23 Lipidor Lipidor publicerar årsredovisning för 2020 Rapporter Ladda ner | Visa Stäng
2021-04-23 Lipidor Lipidor's subsidiary Emollivet takes the next step towards launch and receives funding from Vinnova Pressreleaser Ladda ner | Visa Stäng
2021-04-23 Lipidor Lipidors dotterföretag Emollivet tar nästa steg mot lansering och finansieras av Vinnova Pressreleaser Ladda ner | Visa Stäng
2021-04-22 Lipidor Lipidor - uppdatering om bolagets kliniska Fas III-studie med läkemedelskandidaten AKP02 för behandling av psoriasis Pressreleaser Ladda ner | Visa Stäng
2021-04-22 Lipidor Lipidor - update on the company's phase III clinical trial of drug candidate AKP02 for treatment of psoriasis Pressreleaser Ladda ner | Visa Stäng
2021-03-04 Lipidor Lipidor presenterar på Erik Penser Banks Bolagsdag den 11 mars Pressreleaser Ladda ner | Visa Stäng
2021-02-23 Lipidor Lipidor AB (publ) offentliggör bokslutskommuniké för 2020 Rapporter Ladda ner | Visa Stäng
2021-02-23 Lipidor Lipidor AB (publ) publishes year-end report for 2020 Rapporter Ladda ner | Visa Stäng
2021-01-18 Lipidor Lipidor and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO[®] technology Pressreleaser Ladda ner | Visa Stäng
2021-01-18 Lipidor Lipidor och Cannassure tecknar exklusivt licensavtal avseende topikala medicinska cannabisprodukter baserade på Lipidors AKVANO[®]-teknologi Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

24 Aug 2022 | Kvartalsrapport 2022-Q2
23 Nov 2022 | Kvartalsrapport 2022-Q3